This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignee: Turnstone Biologics Corp.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: David Stojdl: Innovator in Oncolytic Rhabdovirus Research
Introduction
David Stojdl is a prominent inventor based in Ottawa, Canada. He is known for his groundbreaking work in the field of oncolytic rhabdoviruses, particularly their application as anti-cancer therapeutics. His innovative approach focuses on utilizing non-VSV rhabdoviruses to target and kill tumor cells effectively.
Latest Patents
David Stojdl currently holds 1 patents. His notable invention, the Oncolytic Rhabdovirus, includes compositions and methods related to non-VSV rhabdoviruses. These rhabdoviruses exhibit tumor cell killing properties both in vitro and in vivo, showcasing their potential as effective cancer treatments.
Career Highlights
Throughout his career, David has made significant contributions to cancer research. He has worked with esteemed organizations, including the Children's Hospital of Eastern Ontario Research Institute Inc. and Turnstone Limited Partnership. His dedication to advancing medical science has positioned him as a key figure in his field.
Collaborations
David Stojdl has collaborated with various professionals, including his coworker John Cameron Bell. These partnerships have further enhanced his research and development efforts in the realm of oncolytic therapies.
Conclusion
David Stojdl's innovative work in oncolytic rhabdoviruses represents a significant advancement in cancer therapeutics. His contributions to the field continue to inspire future research and development in anti-cancer treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile